These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23033982)

  • 1. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study.
    Kim KC; Yook JH; Eisenbraun J; Kim BS; Huber R
    BMC Complement Altern Med; 2012 Oct; 12():172. PubMed ID: 23033982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.
    Pelzer F; Tröger W; Nat DR
    J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
    Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
    BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
    Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
    Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
    Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects.
    Huber R; Lüdtke H; Wieber J; Beckmann C
    BMC Complement Altern Med; 2011 Nov; 11():116. PubMed ID: 22114899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mistletoe in the treatment of cancer patients].
    Rostock M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 May; 63(5):535-540. PubMed ID: 32211937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients].
    Steuer-Vogt MK; Bonkowsky V; Scholz M; Fauser C; Licht K; Ambrosch P
    HNO; 2006 Apr; 54(4):277-86. PubMed ID: 16132877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
    Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
    Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous infiltrates induced by injection of mistletoe extracts (Iscador).
    Gorter RW; van Wely M; Stoss M; Wollina U
    Am J Ther; 1998 May; 5(3):181-7. PubMed ID: 10099057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.
    Bar-Sela G; Haim N
    Med Oncol; 2004; 21(3):251-4. PubMed ID: 15456952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on local inflammatory reactions and other parameters during subcutaneous mistletoe application in HIV-positive patients and HIV-negative subjects over a period of 18 weeks.
    Stoss M; van Wely M; Musielsky H; Gorter RW
    Arzneimittelforschung; 1999 Apr; 49(4):366-73. PubMed ID: 10337457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.
    Piao BK; Wang YX; Xie GR; Mansmann U; Matthes H; Beuth J; Lin HS
    Anticancer Res; 2004; 24(1):303-9. PubMed ID: 15015612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
    Melzer J; Iten F; Hostanska K; Saller R
    Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
    Büssing A
    Arzneimittelforschung; 2006 Jun; 56(6A):508-15. PubMed ID: 16927532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
    Grossarth-Maticek R; Ziegler R
    Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
    Bar-Sela G; Wollner M; Hammer L; Agbarya A; Dudnik E; Haim N
    Eur J Cancer; 2013 Mar; 49(5):1058-64. PubMed ID: 23218588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
    Schad F; Axtner J; Kröz M; Matthes H; Steele ML
    Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.